Related Experiment Video
Updated: May 16, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
Cannabidiol and Its Effects on Patients with COVID-19 Infection
Yuval Kuntzman1, Gilad Halpert2, Howard Amital3
1Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel, Internal Medicine B, Sheba Medical Center, Tel Hashomer, Israel.
Background:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease pathway is heavily influenced by different inflammatory cytokines. There is ample evidence of cannabidiol (CBD) immunomodulation effects.
Objectives:
To investigate the effect of CBD on patients with SARS-CoV-2 and to measure the impact on inflammatory cytokines.
Methods:
A double blind, placebo-controlled study to compare the clinical outcomes and selected serum cytokine levels in patients with SARS-CoV-2 that received sublingual CBD extraction. Seven patients were randomized to the treatment arm and three to the placebo group.
Results:
Clinical outcomes were better in the patient group that received sublingual CBD vs. patients receiving placebo treatment. Serum cytokine mean concentration levels showed differences between the two groups but of mixed trends.
Conclusions:
Patients presenting with SARS-CoV-2 and receiving CBD sublingually had better outcomes than those receiving a placebo, although these results did not reflect in selected serum cytokines. Further study is needed.
Insights
Cannabidiol (CBD) improved clinical outcomes for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While CBD showed promise, its impact on specific inflammatory cytokines requires further investigation.
Area of Science:
- Immunology and Virology
- Pharmacology and Therapeutics
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease progression is significantly modulated by inflammatory cytokines.
- Cannabidiol (CBD) is recognized for its immunomodulatory properties, suggesting potential therapeutic applications.
Purpose of the Study:
- To evaluate the efficacy of cannabidiol (CBD) in patients diagnosed with SARS-CoV-2.
- To quantify the impact of CBD on key serum inflammatory cytokine levels in SARS-CoV-2 patients.
Main Methods:
- A double-blind, placebo-controlled study design was employed.
- Sublingual CBD extract was administered to seven SARS-CoV-2 patients, with three receiving a placebo.
- Clinical outcomes and serum cytokine concentrations were compared between the treatment and placebo groups.
Main Results:
- Patients treated with sublingual CBD demonstrated improved clinical outcomes compared to the placebo group.
- Serum cytokine levels exhibited differences between groups, but with inconsistent trends.
- The study involved a small sample size (7 CBD, 3 placebo).
Conclusions:
- Sublingual administration of CBD was associated with better clinical outcomes in SARS-CoV-2 patients versus placebo.
- Observed clinical improvements did not consistently correlate with changes in the selected serum cytokines.
- Further research is warranted to elucidate the precise mechanisms and clinical significance of CBD in SARS-CoV-2 management.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Controls in Experiments
COPD: Management Using Bronchodilators and Corticosteroids
Anxiolytic Drugs: Benzodiazepines and Buspirone

